Sound waves against seizures: new device tested for Drug-Resistant epilepsy
NCT ID NCT06492720
First seen Apr 29, 2026 · Last updated Jun 21, 2026 · Updated 6 times
Summary
This pilot study tests a device called NaviFUS that uses low-intensity focused ultrasound to calm overactive brain areas. It involves 16 adults with drug-resistant epilepsy who still have frequent seizures despite trying at least three medications. The goal is to see if the treatment safely reduces seizure frequency over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-intensity focused ultrasound (LIFU) via NaviFUS system
What this could lead to
If it works, this could offer a non-invasive way to reduce seizures in people with epilepsy that doesn't respond to medication.
What could go wrong
This is a very small, early pilot study with only 16 people. It may not show clear benefit, and the effect on seizures could be temporary or inconsistent.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.